抗淀粉样蛋白疗法对阿尔茨海默病有效：为什么需要这么长时间，下一步是什么？
An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?
机构信息
Reta Lilla Weston Research Laboratories, UCL Institute of Neurology, London, WC1N 3BG, UK.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, UK.
出版信息
Brain. 2023 Apr 19;146(4):1240-1242. doi: 10.1093/brain/awad049.
Abstract
Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical practice will be challenging.
摘要
哈迪和马默里讨论了近期在早期阿尔茨海默病中利斯来单抗临床试验的积极发现，以及对淀粉样蛋白假说的影响。他们认为，这些结果标志着阿尔茨海默病领域的一个转折点，但将抗淀粉样蛋白疗法应用于临床实践将具有挑战性。
Zotero 插件